Robust 2026 IPO issuance, with 254 deals priced through mid-October and year-to-date proceeds already surpassing full-year 2025 levels excluding outliers like SpaceX, reflects sustained equity market access for growth companies. Recent SEC filings and pricings in biotech and SPAC sectors, including Iambic Therapeutics and City Therapeutics slated for mid-October, underscore an active pipeline into year-end. However, high-profile delays—OpenAI citing safety priorities and Anthropic targeting post-midterm timing—highlight selectivity driven by valuation discipline, AI sector volatility, and Treasury yield levels. Trader sentiment in associated prediction markets aggregates these execution risks and catalysts around FOMC decisions and earnings windows.